Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 1,827 |
|
|||||
| News | - | ||||||
| Day High | 2.37 | Low High |
|||||
| Day Low | 2.28 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Finch Therapeutics Group Inc | FNCH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0693 | 3.09% | 2.3093 | 15:53:14 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.29 | 2.28 | 2.37 | 2.3093 | 2.24 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 49 | 1,827 | US$ 2.30 | US$ 4,204 | - | 1.86 - 16.74 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:19:08 | 1 | US$ 2.24 | USD |
Finch Therapeutics Group Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.71M | 1.61M | - | 107k | -74.75M | -46.55 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Finch Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/23/2024 | 15:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/13/2023 | 16:20 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 11/17/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/08/2023 | 05:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/11/2023 | 05:31 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:.. |
| 8/10/2023 | 05:31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/07/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/28/2023 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/09/2023 | 06:00 | GlobeNewswire Inc. | Finch Announces Reverse Stock Split of Common Stock |
| 5/10/2023 | 06:00 | GlobeNewswire Inc. | Finch Therapeutics Reports First Quarter 2023 Financial.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FNCH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.48 | 2.63 | 2.095 | 2.29 | 50,207 | -0.1707 | -6.88% |
| 1 Month | 2.45 | 3.37 | 1.86 | 2.75 | 101,301 | -0.1407 | -5.74% |
| 3 Months | 2.76 | 4.46 | 1.86 | 2.82 | 48,234 | -0.4507 | -16.33% |
| 6 Months | 3.89 | 5.70 | 1.86 | 3.06 | 35,338 | -1.58 | -40.63% |
| 1 Year | 11.997 | 16.74 | 1.86 | 6.88 | 43,774 | -9.69 | -80.75% |
| 3 Years | 423.60 | 663.00 | 1.86 | 95.78 | 157,263 | -421.29 | -99.45% |
| 5 Years | 613.50 | 675.00 | 1.86 | 115.45 | 158,465 | -611.19 | -99.62% |
Finch Therapeutics Description
| Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection. |
